Mayo-Smith W W, Schima W, Saini S, Slater G J, McFarland E G
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.
AJR Am J Roentgenol. 1998 Mar;170(3):649-52. doi: 10.2214/ajr.170.3.9490946.
The purpose of this study was to evaluate pancreatic enhancement with low-dose mangafodipir trisodium (5 mumol/kg) using three different T1-weighted pulse sequences.
Fifteen patients, six of whom had proven focal pancreatic tumors, underwent T1-weighted gradient-recalled echo imaging, spin-echo imaging, and fat-suppressed spin-echo imaging before and 30 min after injection of 5 mumol/kg of mangafodipir trisodium. Region-of-interest measurements were obtained in the pancreas before and after contrast enhancement. Signal-to-noise ratios were calculated in all 15 patients. Contrast-to-noise ratios were calculated in the six patients with pancreatic tumors.
The signal-to-noise ratios of the pancreas increased after injection of mangafodipir trisodium on all three T1-weighted pulse sequences (p < .001). Enhanced fat-suppressed sequences (29 +/- 7.7) and gradient-recalled echo sequences (29 +/- 9.6) had the highest signal-to-noise ratios. Contrast-to-noise ratios between normal pancreatic tissue and pancreatic tumor also increased after contrast administration (p < .05) and were highest on the fat-suppressed (-9.6 +/- 4.0) pulse sequence.
Mangafodipir trisodium produced marked pancreatic enhancement at a dose of 5 mumol/kg for all three T1-weighted pulse sequences. The enhanced T1-weighted spin-echo fat-suppressed sequence showed the highest signal-to-noise and contrast-to-noise ratios.
本研究旨在使用三种不同的T1加权脉冲序列评估低剂量锰福地匹三钠(5 μmol/kg)对胰腺的增强效果。
15例患者,其中6例已证实患有胰腺局灶性肿瘤,在注射5 μmol/kg锰福地匹三钠前及注射后30分钟接受了T1加权梯度回波成像、自旋回波成像和脂肪抑制自旋回波成像。在对比剂增强前后,在胰腺中进行感兴趣区测量。计算了所有15例患者的信噪比。计算了6例胰腺肿瘤患者的对比噪声比。
在所有三种T1加权脉冲序列上,注射锰福地匹三钠后胰腺的信噪比均升高(p <.001)。增强脂肪抑制序列(29±7.7)和梯度回波序列(29±9.6)具有最高的信噪比。对比剂注射后,正常胰腺组织与胰腺肿瘤之间的对比噪声比也升高(p <.05),在脂肪抑制(-9.6±4.0)脉冲序列上最高。
对于所有三种T1加权脉冲序列,锰福地匹三钠在剂量为5 μmol/kg时均能产生明显的胰腺增强。增强的T1加权自旋回波脂肪抑制序列显示出最高的信噪比和对比噪声比。